pemphigus|pemphigi in English

noun

disease characterized by vesicles on the skin and mucous membranes (Pathology)

Use "pemphigus|pemphigi" in a sentence

Below are sample sentences containing the word "pemphigus|pemphigi" from the English Dictionary. We can refer to these sentence patterns for sentences in case of finding sample sentences with the word "pemphigus|pemphigi", or refer to the context using the word "pemphigus|pemphigi" in the English Dictionary.

1. Pemphigus: Top-Layer Blistering

2. Pemphigus of the larynx and esophagus.

3. Pemphigus Blistering disorders of the skin form blisters intraepidermally.

4. The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (Absis) scores have been proposed to provide an objective measure of pemphigus activity

5. Histological hallmarks of IgA pemphigus are epidermal acantholysis, subcorneal or intraepidermal pustulosis, and neutrophilic infiltration.

6. More investigations should be needed to explain the exact role of complement in pemphigus acantholysis.

7. Types of Autoimmune Blistering Skin Diseases Autoimmune Blistering skin diseases include: Pemphigus: A group of intraepidermal Blistering disorders that cause erosions and/or sores on the skin, mouth, throat, nose, eyes, scalp, or genitals (includes pemphigus vulgaris and pemphigus foliaceous); Pemphigoid: A group of subepidermal Blistering disorders that cause vesicles, blisters, erosions

8. Bullous pemphigus is a self-limited disease, but may last from months to years

9. The patient also suffered from a testicular feminization syndrome and was treated with immunosuppressive drugs for pemphigus vulgaris.

10. Cabaletta Bio Announces FDA Orphan Drug Designation for DSG3- CAART for the Treatment of Pemphigus Vulgaris

11. Pemphigus autoantibodies, bound in the epidermis during different stages of acantholysis, were demonstrated with a new techniques for immunoelectron microscopy.

12. The epidermal changes induced by cantharidin and pemphigus-acantholysis are based on fundamentally different pathogenetic mechanisms and, therefore, not comparable.

13. Our understanding of the mechanisms of epidermal cell adhesion has Arisenin part from a different clinical story—that of pemphigus

14. New Biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature Int J Womens Dermatol

15. It is useful in differentiating between the diagnosis of pemphigus vulgaris or mucous membrane pemphigoid (where the sign is present) and bullous pemphigoid (where it is absent).

16. In pemphigus the intercellular spaces are primarily widened and, after the disappearance of desmosomes, the cells separate in toto. This process represents true acantholysis.

17. IgA pemphigus is a rare intraepidermal autoimmune disease characterized by the presence of intercellular IgA deposits, intraepidermal acantholysis with infiltration of neutrophils, and circulating IgA autoantibodies against keratinocyte cell surface components.

18. In IgG-mediated diseases, immunosuppression with corticosteroids and steroid-sparing agents should be initiated, although only local therapy is sufficient to control a self-limiting pemphigus neonatorum.

19. While the term pemphigus typically refers to "a rare group of blistering autoimmune diseases" affecting "the skin and mucous membranes", Hailey–Hailey disease is not an autoimmune disorder and there are no autoantibodies.

20. The inflammatory skin conditions may include acne vulgaris, allergic dermatitis, alopecia areata, androgenetic alopecia, atopic dermatitis, dandruff, dermatitis herpetiformis, discoid lupus erythematosus, pemphigus, primary cicatricial alopecia, psoriasis, seborrheic dermatitis, and ultraviolet and thermal burns.

21. Disclosure of the use of FasL antagonists, e.g. of humanized antibodies directed against human Fas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL) for the prevention and/or treatment of skin diseases associated with keratinocytes acantholysis, particularly for the prevention and/or treatment of pemphigus.

22. The present invention refers to the use of FasL antagonists, e.g. of humanized antibodies directed against human Fas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL) for the prevention and/or treatment of skin diseases associated with keratinocytes acantholysis, particularly for the prevention and/or treatment of pemphigus.